MariMed (MRMD, Financial) has unveiled an innovative product line called MycroDose by Nature’s Heritage, which merges full-spectrum cannabis with functional mushrooms into a vegan-friendly wellness solution. This new range offers four distinct formulations aimed at enhancing various aspects of well-being, such as mental clarity, relaxation, focus, and overall health, all available in a convenient pill form.
The MycroDose collection is currently available in Massachusetts, both at MariMed’s Panacea Wellness outlets and selected dispensaries. Each product is crafted with a unique combination of natural vegan ingredients. The line-up includes Chill, formulated with THC, CBD, Organic Cordyceps, Organic Lion’s Mane, and Ashwagandha for relaxation. G’Night, which promotes better sleep with THC, CBN, CBD, Organic Reishi, Organic Lion’s Mane, Chamomile, and Magnesium. Remedy, aimed at reducing inflammation and calming the mind, contains THC, CBD, CBC, Oyster mushroom, Ginger root, Turmeric, and Piperine. Finally, Spark is designed to boost energy and focus using Shiitake mushrooms, Organic Lion’s Mane, Ginseng, THCV, and THC.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for MariMed Inc (MRMD, Financial) is $0.23 with a high estimate of $0.25 and a low estimate of $0.20. The average target implies an
upside of 200.96%
from the current price of $0.07. More detailed estimate data can be found on the MariMed Inc (MRMD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, MariMed Inc’s (MRMD, Financial) average brokerage recommendation is currently 2.0, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for MariMed Inc (MRMD, Financial) in one year is $0.36, suggesting a
upside
of 381.54% from the current price of $0.07476. GF Value is GuruFocus’ estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business’ performance. More detailed data can be found on the MariMed Inc (MRMD) Summary page.
MRMD Key Business Developments
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- MariMed Inc (MRMD, Financial) reported a 16% year-over-year increase in wholesale gross revenue, indicating strong market penetration.
- The company successfully expanded its brand presence, selling products into 70 new storefronts during the quarter.
- MariMed Inc (MRMD) is actively pursuing M&A opportunities and licensing deals to enter new high-growth markets, which could drive future growth.
- The company is launching innovative new products, such as the Microdose by Nature’s Heritage, which taps into the growing trend of functional mushrooms.
- MariMed Inc (MRMD) maintains a strong balance sheet with $7.2 million in cash and cash equivalents, supporting its strategic initiatives.
Negative Points
- Overall revenue for the quarter was flat year-over-year, reflecting challenges in the retail segment.
- The company reported a net loss of $5.4 million for the quarter, an increase from the previous year’s loss of $1.3 million.
- Gross margins declined to 41.3% from 43.8% in the same period last year, primarily due to price compression and increased costs.
- Retail revenue decreased by 7% year-over-year, impacted by market challenges and economic uncertainty.
- MariMed Inc (MRMD) faces challenges in the Missouri market due to strong local operator networks and reciprocity issues.
